(Q40284794)

19 September 2017

title

Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products (English)

1 reference

19 September 2017

Miriam E R Darnell

1

1 reference

19 September 2017

Deborah R Taylor

series ordinal

2

1 reference

19 September 2017

publication date

1 October 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

46

1 reference

19 September 2017

issue

10

1 reference

19 September 2017

page(s)

1770-1777

1 reference

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

A novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Viral loads in clinical specimens and SARS manifestations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Direct and indirect effects of UV radiation on DNA and its components

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Severe acute respiratory syndrome (SARS)--paradigm of an emerging viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Detection of severe acute respiratory syndrome coronavirus RNA in plasma during the course of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Reducing the risk of infection from plasma products: specific preventative strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Heat sensitivity of a SARS-associated coronavirus introduced into plasma products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Stability and inactivation of SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Design of a UV-C irradiation process for the inactivation of viruses in protein solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Pathogen inactivation technology: cleansing the blood supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00976.X

Inactivation of lipid-enveloped viruses in proteins by caprylate

21 January 2018

1 reference

12 December 2020

Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants.

1 reference

12 December 2020

Distribution and repair of bipyrimidine photoproducts in solar UV-irradiated mammalian cells. Possible role of Dewar photoproducts in solar mutagenesis

1 reference

12 December 2020

Identification and containment of an outbreak of SARS in a community hospital

1 reference

12 December 2020

Viral safety of solvent-detergent treated blood products.

1 reference

12 December 2020

Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation.

1 reference

12 December 2020

10.1111/J.1537-2995.2006.00976.X

Identifiers

DOI

1 reference

release_zbr6e4fwqzcn5aulp7jwph54vi

19 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zbr6e4fwqzcn5aulp7jwph54vi

24 November 2022

mapped directly with Wikidata item

1 reference